Furthermore, five genes (CAPN3, CRISPLD2, RARRES1, PLAAT4, and HMGCS2) were confirmed to be upregulated in lenvatinib-treated HCC cells by RT-qPCR and western blot assays (Fig. 1D-E). This evidence concerns the gene PLAAT4 and hepatocellular carcinoma.